Trials / Active Not Recruiting
Active Not RecruitingNCT06987695
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (MARITIME 3-J)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 279 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart cafraglutide | Maridebart cafraglutide will be administered SC. |
| DRUG | Placebo | Placebo will be administered SC. |
Timeline
- Start date
- 2025-06-13
- Primary completion
- 2027-04-27
- Completion
- 2027-07-21
- First posted
- 2025-05-23
- Last updated
- 2025-12-17
Locations
30 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06987695. Inclusion in this directory is not an endorsement.